Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Bates Website

Susan Bates, M.D.

Selected Publications

1)  Fojo AT, Bates SE.
Clinical trial results: a clinical trial bazaar!.
Oncologist. 19: 313-4, 2014.
[Journal]
2)  Rubin EH, Allen JD, Nowak JA, Bates SE.
Developing precision medicine in a global world.
Clin. Cancer Res. 20: 1419-27, 2014.
[Journal]
3)  Bates SE.
It"s All About the Test: The Complexity of Companion Diagnostic Co-development in Personalized Medicine.
Clin. Cancer Res. 20: 1418, 2014.
[Journal]
4)  Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Ambudkar SV, Bates SE, Fu LW, Chen ZS.
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Int. J. Biochem. Cell Biol. 2014.
[Journal]
5)  Bates SE.
A sea change in melanoma.
Clin. Cancer Res. 19: 5282, 2013.
[Journal]
6)  Fojo AT, Bates SE, Chabner BA.
Clinical trial results: sharing results, speeding discoveries.
Oncologist. 18: 779, 2013.
[Journal]
7)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
[Journal]
8)  Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S.
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.
Cancer Biol. Ther. 14: 175-83, 2013.
[Journal]
9)  Ierano C, Chakraborty AR, Nicolae A, Bahr JC, Zhan Z, Pittaluga S, Bates SE, Robey RW.
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Cell Cycle. 12: 2829-38, 2013.
[Journal]
10)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. 121: 4115-25, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/23/2014.